The Changing Treatment Landscape for Renal Cell Carcinoma: Bradley McGregor, MD

Within the last few years, treatment of renal cell carcinoma has improved dramatically, with FDA approvals of several agents and numerous others in development. In this interview, Bradley McGregor, MD, Clinical Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, highlights these exciting developments and sheds light on the additional progress that is underway for the treatment of renal cell carcinoma. Onc...
Continue reading

Exploring Treatment Options for Patients With Renal Cell Carcinoma: Bradley McGregor, MD, and Robert Motzer, MD

In 2021, an estimated 76,080 new cases of kidney cancer will be diagnosed. Among those cases, the majority will be renal cell carcinomas (RCC). In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Expert Guidance on New Advances in Renal Cell Carcinoma, Bradley McGregor, MD, Clinical Director of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, and Robert Motzer, MD, Chair ...
Continue reading

CK2 Inhibitor Disrupts Cancer’s Circadian Rhythm

Circadian rhythm is an important internal biological clock in charge of daily physiological processes. It regulates the sleep/wake cycle, body temperature, hormone secretion, and energy metabolism. Cells in the human body are dictated by their own circadian rhythm. According to a new study published in Science Advances, manipulating cancerous cells' circadian rhythm could potentially harm or kill malignancies by stunting their growth. In this study, researchers from the University of Southern Ca...
Continue reading

Kidney Cancer: CT Scan Enhancement Avoids Unneeded Surgery

In a new study published in Clinical Cancer Research, researchers have found a radiographic measure that can differentiate a benign type of kidney tumor from a potentially deadly one, eliminating the need for unnecessary surgeries. According to senior author Eric Kauffman, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer Center, kidney tumors are unusual in that a biopsy cannot always confirm whether they are cancerous or benign. Tumor biopsies that test positive for...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.